Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying”

Group 1 - Abbott Laboratories is acquiring Exact Sciences for approximately $21 billion, representing a 51% premium over its previous trading price, marking the largest healthcare deal in two years and the largest diagnostic acquisition ever [1] - The acquisition is expected to enhance Abbott's diagnostic business, particularly in colorectal cancer screening, leveraging Exact Sciences' strong product offerings [1] - The deal's approval is anticipated to be smoother under the Trump administration compared to the Biden administration, which has shown a more hostile stance towards mergers [1] Group 2 - Abbott Laboratories develops and sells a variety of healthcare products, including generic medicines, diagnostic systems, nutrition brands, cardiovascular and diabetes care devices, and neuromodulation technologies [2]